Rush 1998.

Methods	Eight‐week randomised, double‐blind multicentre study
Participants	Outpatients fulfilling DSM‐III criteria for moderate to severe major depressive disorder, non psychotic, with a score of at least 18 on the first 17 items of the Hamilton Rating Scale for Depression‐17 item (HDRS‐17). Age range: 19‐55 years Exclusion criteria: engaged in a shift work, independent sleep/wake disorders, significant concurrent general medical conditions, DSM‐III criteria for psychoactive use disorder within 1 year prior to study, other major lifetime Axis I disorders (organic mental syndrome, bipolar, any psychotic, any eating,panic or obsessive‐compulsive disorder), pregnancy, lactation, absence of contraception.
Interventions	Fluoxetine: 61 participants Nefazodone: 64 participants Fluoxetine dose range: 20‐40 mg/day Nefazodone dose range: 200‐500 mg/day
Outcomes	HDRS‐17 total score, Inventory of Depressive Symptomatology (IDS), Clinical Global Impression (CGI) Improvement
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no further information
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double dummy dosing regimen was employed", no further information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Number and reasons for dropout reported. Scores reported with denominator
Selective reporting (reporting bias)	Unclear risk	Only most common side effects reported
Other bias	High risk	Quote: "this study was sponsored by Bristol‐Myers Squibb Pharmaceutical research Institute", this company produces nefazodone